4-Formyloxy-2-methylbutanoic acid | 94924-63-7

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 脂肪酰基
• 英文名称: 4-Formyloxy-2-methylbutanoic acid
• CAS: 94924-63-7
• 化学式: C₆H₁₀O₄
• mdl: MFCD19231161
• 分子量: 146.143
• InChiKey: GLCPVCGADWLDAC-UHFFFAOYSA-N

物化性质

• 沸点：
  271.9±23.0 °C(Predicted)
• 密度：
  1.157±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.6
• 重原子数：
  10
• 可旋转键数：
  5
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.666
• 拓扑面积：
  63.6
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为产物：
  描述：

  3,4-二氢-4-甲基-2H-吡喃 在 ruthenium(IV) oxide 、 sodium periodate 作用下， 以 四氯化碳 为溶剂， 反应 40.0h， 以53%的产率得到4-Formyloxy-2-methylbutanoic acid
  参考文献：
  名称：

  A facile procedure for oxidative cleavage of enolic olefins to the carbonyl compounds with ruthenium tetroxide (RuO4)

  摘要：

  DOI：

  10.1021/jo00224a071

文献信息

• QUINAZOLINE DERIVATIVE, COMPOSITION HAVING THE DERIVATIVE, AND USE OF THE DERIVATIVE IN PREPARING MEDICAMENT
  申请人：Wang Shulong

  公开号：US20150080392A1

  公开（公告）日：2015-03-19

  A class of quinazoline derivatives or pharmaceutically acceptable salts or solvates thereof with novel structures is provided; meanwhile, a pharmaceutical composition comprising a pharmaceutically effective amount of said quinazoline derivatives or pharmaceutically acceptable salts or solvates thereof, and pharmaceutically acceptable excipients or additives is also provided. By modifying and transforming the quinazoline and screening of the transformed compounds on the activity of tyrosine kinase inhibition, most of the compounds have been found to possess inhibitory activity against one or several of EGFR, VEGFR-2, c-erbB-2, c-erbB-4, c-met, tie-2, PDGFR, c-src, lck, Zap70 and fyn kinases. The present invention has the advantages of reasonable design, broad source of and easy access to the raw materials, simple and easy operation of the preparation methods, mild reaction conditions, high yield of the products and being beneficial for industrial-scale production.

  提供一类具有新颖结构的喹唑啉衍生物或其药用可接受的盐或溶剂；同时，还提供了一种包含所述喹唑啉衍生物或其药用可接受的盐或溶剂的药物组合物，以及药用可接受的赋形剂或添加剂。通过修改和转化喹唑啉，并对转化后的化合物在酪氨酸激酶抑制活性上的筛选，发现大多数化合物对EGFR、VEGFR-2、c-erbB-2、c-erbB-4、c-met、tie-2、PDGFR、c-src、lck、Zap70和fyn激酶中的一个或几个具有抑制活性。本发明具有设计合理、原料来源广泛且易获得、制备方法简单易行、反应条件温和、产品产率高且有利于工业规模生产的优点。
• FUSED HETEROAROMATIC CYCLOPENTENE DERIVATIVE HAVING ENDOTHELIN-ANTAGONIST ACTIVITY
  申请人：BANYU PHARMACEUTICAL CO., LTD.

  公开号：EP0714897A1

  公开（公告）日：1996-06-05

  A cyclopentene derivative represented by general formula (I) and a pharmaceutically acceptable salt thereof: wherein Ar¹ and Ar² represent each independently phenyl, thienyl, pyridyl, indolyl, benzofuranyl or dihydrobenzofuranyl; A represents a group that is combined with the adjacent carbon-carbon double bond to form a 5-or 6-membered heteroaromatic ring containing one to four heteroatoms selected from the group consisting of nitrogen, oxygen and sulfur; and Y represents -CO-R⁴, SO₃H, PO₃H₂, tetrazol-5-yl, 2-oxo-3H-1,2,3,5-oxathiadiazol-4-yl or 5-oxo-4H-1,2,4-oxadiazol-3-yl.

  通式 (I) 所代表的环戊烯衍生物及其药学上可接受的盐：其中 Ar¹ 和 Ar² 各自独立地代表苯基、噻吩基、吡啶基、吲哚基、苯并呋喃基或二氢苯并呋喃基；A 代表一个基团，该基团与相邻的碳碳双键结合形成一个 5 或 6 元杂芳环，该环含有一至四个杂原子，这些杂原子选自由氮、氧和硫组成的组；Y 代表-CO-R⁴、SO₃H、PO₃H₂、四唑-5-基、2-氧代-3H-1,2,3,5-噁二唑-4-基或 5-氧代-4H-1,2,4-噁二唑-3-基。
• ENDOTHELIN ANTAGONISTS FOR TREATING HEART FAILURE
  申请人：BANYU PHARMACEUTICAL CO., LTD.

  公开号：EP0906108B1

  公开（公告）日：2005-06-15
• EP2855418B1
  申请人：——

  公开号：EP2855418B1

  公开（公告）日：2017-08-09
• US5714479A
  申请人：——

  公开号：US5714479A

  公开（公告）日：1998-02-03